1. Scrip
  2. >>New Products

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

 
• By Joseph Haas

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Cholesterol plaque in artery
Nexletol's unique mechanism of action inhibits the synthesis of cholesterol in the liver

The approval of Esperion Therapeutics Inc.’s Nexletol (bempedoic acid) will kick start competition in the cholesterol space as the oral drug, which has a new mechanism of action, goes up against drugs like the PCSK9 inhibitors currently on the market and Novartis AG’s RNA-interference candidate inclisiran, which is slated for US approval before the end of 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies